Curated News
By: NewsRamp Editorial Staff
June 03, 2025
Kairos Pharma's KROS101 Shows Promise in Cancer Immunotherapy at ASCO 2025
TLDR
- Kairos Pharma's KROS101 outperforms TRX518 in enhancing T cell activity and reducing immune suppression, offering a competitive edge in cancer immunotherapy.
- KROS101, a small molecule GITR ligand agonist, works by boosting effector T cell activity and reducing T reg cells, demonstrating a dual mechanism in preclinical studies.
- Kairos Pharma's KROS101 advances cancer treatment by stimulating immune response and tumor destruction, promising a better future for patients worldwide.
- Discover how Kairos Pharma's KROS101 is revolutionizing cancer immunotherapy with its unique dual mechanism, showcased at ASCO 2025.
Impact - Why it Matters
This news is significant as it highlights a potential breakthrough in cancer treatment, offering hope for patients with resistant forms of cancer. KROS101's dual mechanism could pave the way for more effective immunotherapies, addressing a critical need in oncology. The advancement of ENV105 also represents a promising avenue for overcoming drug resistance, a major challenge in cancer therapy today.
Summary
Kairos Pharma Ltd. (NYSE American: KAPA) has unveiled promising preclinical data for its investigational small molecule GITR ligand agonist, KROS101, at the ASCO 2025 Annual Meeting. The study highlights KROS101's unique ability to enhance effector T cell activity and reduce immune-suppressive T reg cells, showcasing superior performance over TRX518 in tumor infiltration, cytotoxicity, and preventing T cell exhaustion. Dr. John Yu, CEO, underscores KROS101's potential to revolutionize cancer immunotherapy by simultaneously boosting immune response and tumor destruction. For more details, the full press release is available here.
Kairos Pharma, based in Los Angeles, is pioneering oncology therapeutics with its lead candidate, ENV105, targeting CD105 to combat drug resistance in cancer. ENV105 is currently in Phase 2 trials for castrate resistant prostate cancer and Phase 1 for lung cancer, aiming to address critical unmet medical needs. Discover more about their innovative approach at www.KairosPharma.com.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Kairos Pharma's KROS101 Shows Promise in Cancer Immunotherapy at ASCO 2025
